Clinical Trial Update: Comparison of Two Formulations of AZD5363 and the Effect of Food on Pharmacokinetic Exposure, Safety and Tolerability [Phase 1]

View source ↗

Summary

Phase 1 study comparing two formulations of AZD5363 and evaluating the effect of food on pharmacokinetics, safety, and tolerability in patients with advanced so…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Malignancies

Drugs mentioned

• AZD5363 (capivasertib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Malignancy,, Safety and Tolerability, | Phase 1 | Status: COMPLETED | Results posted: 2016-05-25